Skip to content

Introduction of a Diet as add-on therapy for remission maintenance in IBD

Introduction of a Diet as add-on therapy for remission maintenance in IBD - Diet and IBD in remission

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON46767
Enrollment
80
Registered
2018-02-16
Start date
2018-03-16
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

crohns disease inflammatory bowel disease ulcerative colitis

Interventions

Patients will enter a nutritional intervention program, coordinated by Stichting voeding leeft. Control subjects will continue their regular diet.

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients with IBD in remission (fecal calprotectin (fCAL)

Exclusion criteria

Exclusion criteria: Patients unable or unwilling to provide informed consent. Stenosis associated with symptoms. Current healthy lifestyle (as there will be nothing to optimize using our nutritional intervention program).

Design outcomes

Primary

MeasureTime frame
We aim to assess the feasability of a nutritional intervention as add-on treatment (next to standard medical treatment) in patients with IBD in remission

Secondary

MeasureTime frame
Secondary objectives are to study the effect of the nutritional intervention program on: 1. Quality of life and Food related quality of life (FR-QoL) 2. Activity of IBD (as assessed using Harvey-Bradshaw index (HBI) or partial Mayo score (pMS) and fecal calprotectin) 3. Nutritional status and anthropometry (body weight, hand grip strength, waist-hip ratio) 4. CAP value (Fibroscan; liver fat content) 5. Immunological assessment of Th17/Treg balance in the peripheral blood of patients to assess effect of our lifestyle intervention program on the pro-inflammatory / anti-inflammatory balance in the peripheral blood of patients And in a subset of patients: 6. AGE reader

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)